Obesity And Disease-Free Survival In Patients With Nodal-Positive Early-Stage Breast Cancer: The Adebar Trial.

541 Background: The prevalence of obesity increases throughout all evolved civilizations. On the other hand several epidemiological studies have shown not only an increase in breast cancer among obese women but also an adverse impact of obesity on survival of breast cancer patients. This analysis focuses on the impact of obesity on patients (pts) treated within the ADEBAR study protocol. Methods: The ADEBAR Trial compared 4 cycles of EC followed by 4 cycles of Docetaxel vs. 8 cycles of FEC (120) in pts with primary breast cancer (> = 4LN). 1500 pts have been accrued from sep/01 through may/05. For this analysis data of 1,361 pts has been analyzed about the impact of obesity on disease free survival. Therefore pts have been grouped to either “underweight” (BMI < 18.5 kg/m2), ”normal weight” (BMI 18.5-25 kg/m2), ”overweight” (25 kg/m230). Results: 13 pts (1.0%) were “underweight”, 557 pts (40.9%) were normal weight, 491 pts (36.1%) were overweight, 300 pts (22.0%) were obese at the time of study enrollment. After a follow up period of 60 months 87.5% of the underweight group, 70.4% of the normal weight group, 70.7% of the overweight group and 58.6% of the obese group were alive with no signs of recurrent disease. This difference was significant (Chi- square = 9.355; p < 0.0249). Conclusions: This analysis strongly implicates an impact of obesity on disease free survival in patients with early stage node positive breast cancer in the prospectively randomized ADEBAR multicenter trial. It is therefore in line with earlier findings in epidemiological research and raises the question whether a weight reduction might be an additional approach on breast cancer therapy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis Amgen, Johnson & Johnson, Novartis, sanofi-aventis Amgen, sanofi-aventis